Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.25
DYAX's Cash to Debt is ranked higher than
59% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. DYAX: 2.25 )
DYAX' s 10-Year Cash to Debt Range
Min: 0.37   Max: 32.79
Current: 2.25

0.37
32.79
Equity to Asset 0.49
DYAX's Equity to Asset is ranked higher than
62% of the 1086 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. DYAX: 0.49 )
DYAX' s 10-Year Equity to Asset Range
Min: -0.93   Max: 0.76
Current: 0.49

-0.93
0.76
F-Score: 4
Z-Score: 18.49
M-Score: -1.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -1.51
DYAX's Operating margin (%) is ranked higher than
82% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. DYAX: -1.51 )
DYAX' s 10-Year Operating margin (%) Range
Min: -389.57   Max: -1.51
Current: -1.51

-389.57
-1.51
Net-margin (%) -14.53
DYAX's Net-margin (%) is ranked higher than
79% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. DYAX: -14.53 )
DYAX' s 10-Year Net-margin (%) Range
Min: -393.89   Max: -14.53
Current: -14.53

-393.89
-14.53
ROE (%) -13.39
DYAX's ROE (%) is ranked higher than
79% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. DYAX: -13.39 )
DYAX' s 10-Year ROE (%) Range
Min: -1406.43   Max: -17.98
Current: -13.39

-1406.43
-17.98
ROA (%) -6.06
DYAX's ROA (%) is ranked higher than
81% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. DYAX: -6.06 )
DYAX' s 10-Year ROA (%) Range
Min: -89.25   Max: -6.76
Current: -6.06

-89.25
-6.76
ROC (Joel Greenblatt) (%) -24.05
DYAX's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. DYAX: -24.05 )
DYAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1121.26   Max: -21.55
Current: -24.05

-1121.26
-21.55
Revenue Growth (3Y)(%) 7.60
DYAX's Revenue Growth (3Y)(%) is ranked higher than
79% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: 2.50 vs. DYAX: 7.60 )
DYAX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -37.4   Max: 21.1
Current: 7.6

-37.4
21.1
EBITDA Growth (3Y)(%) -100.00
DYAX's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. DYAX: -100.00 )
DYAX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -100   Max: 10.4
Current: -100

-100
10.4
EPS Growth (3Y)(%) -36.40
DYAX's EPS Growth (3Y)(%) is ranked higher than
58% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. DYAX: -36.40 )
DYAX' s 10-Year EPS Growth (3Y)(%) Range
Min: -37.4   Max: 11.9
Current: -36.4

-37.4
11.9
» DYAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

DYAX Guru Trades in Q1 2014

Steven Cohen 960,155 sh (New)
Louis Moore Bacon 75,000 sh (New)
Jim Simons 742,804 sh (+40.68%)
PRIMECAP Management 11,806,990 sh (unchged)
Chuck Royce 485,600 sh (-39.98%)
Paul Tudor Jones 16,099 sh (-70.38%)
» More
Q2 2014

DYAX Guru Trades in Q2 2014

Joel Greenblatt 46,505 sh (New)
Steven Cohen 44,100 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 11,129,830 sh (-5.74%)
Chuck Royce 380,200 sh (-21.71%)
Jim Simons 469,186 sh (-36.84%)
» More
Q3 2014

DYAX Guru Trades in Q3 2014

Paul Tudor Jones 17,323 sh (New)
Steven Cohen 56,500 sh (+28.12%)
Jim Simons Sold Out
PRIMECAP Management 10,884,960 sh (-2.20%)
Joel Greenblatt 44,152 sh (-5.06%)
Chuck Royce 244,900 sh (-35.59%)
» More
Q4 2014

DYAX Guru Trades in Q4 2014

Paul Tudor Jones 25,023 sh (+44.45%)
Joel Greenblatt 52,618 sh (+19.17%)
Steven Cohen Sold Out
PRIMECAP Management 10,869,860 sh (-0.14%)
Chuck Royce 179,600 sh (-26.66%)
» More
» Details

Insider Trades

Latest Guru Trades with DYAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 36.30
DYAX's P/B is ranked lower than
62% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. DYAX: 36.30 )
DYAX' s 10-Year P/B Range
Min: 2.05   Max: 74.67
Current: 36.3

2.05
74.67
P/S 47.00
DYAX's P/S is ranked higher than
51% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 37.00 vs. DYAX: 47.00 )
DYAX' s 10-Year P/S Range
Min: 2.46   Max: 48.67
Current: 47

2.46
48.67
EV-to-EBIT -48.23
DYAX's EV-to-EBIT is ranked higher than
65% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DYAX: -48.23 )
DYAX' s 10-Year EV-to-EBIT Range
Min: -3146   Max: -2
Current: -48.23

-3146
-2
Current Ratio 9.52
DYAX's Current Ratio is ranked higher than
87% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. DYAX: 9.52 )
DYAX' s 10-Year Current Ratio Range
Min: 1.72   Max: 9.52
Current: 9.52

1.72
9.52
Quick Ratio 9.31
DYAX's Quick Ratio is ranked higher than
87% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. DYAX: 9.31 )
DYAX' s 10-Year Quick Ratio Range
Min: 1.72   Max: 9.31
Current: 9.31

1.72
9.31
Days Inventory 192.72
DYAX's Days Inventory is ranked higher than
82% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. DYAX: 192.72 )
DYAX' s 10-Year Days Inventory Range
Min: 124.07   Max: 821.79
Current: 192.72

124.07
821.79
Days Sales Outstanding 54.58
DYAX's Days Sales Outstanding is ranked higher than
86% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. DYAX: 54.58 )
DYAX' s 10-Year Days Sales Outstanding Range
Min: 37.74   Max: 101.42
Current: 54.58

37.74
101.42

Valuation & Return

vs
industry
vs
history
Price/Net Cash 52.20
DYAX's Price/Net Cash is ranked higher than
56% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 109.90 vs. DYAX: 52.20 )
DYAX' s 10-Year Price/Net Cash Range
Min: 7.57   Max: 251.17
Current: 52.2

7.57
251.17
Price/Net Current Asset Value 45.40
DYAX's Price/Net Current Asset Value is ranked higher than
54% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 45.70 vs. DYAX: 45.40 )
DYAX' s 10-Year Price/Net Current Asset Value Range
Min: 5.84   Max: 62.79
Current: 45.4

5.84
62.79
Price/Tangible Book 36.10
DYAX's Price/Tangible Book is ranked lower than
62% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. DYAX: 36.10 )
DYAX' s 10-Year Price/Tangible Book Range
Min: 1.05   Max: 72
Current: 36.1

1.05
72
Price/Median PS Value 5.70
DYAX's Price/Median PS Value is ranked higher than
61% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. DYAX: 5.70 )
DYAX' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 2.87
Current: 5.7

0.15
2.87
Earnings Yield (Greenblatt) -2.10
DYAX's Earnings Yield (Greenblatt) is ranked lower than
72% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. DYAX: -2.10 )
DYAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.1   Max: 0
Current: -2.1

-2.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DY8.Germany,
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for DYAX

Headlines

Articles On GuruFocus.com
Voltari Corp. (VLTC) Under Carl Icahn Umbrella, Dyax Corp. (DYAX) Potential Angioedema Preventive Tr Apr 01 2015 
Weekly CFO Buys Highlight: DYAX, IBI, FARM, TAP, DBM Mar 19 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. Reports Operating Results (10-K) Mar 02 2011 
Dyax Corp. Reports Operating Results (10-Q) Nov 02 2010 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 5,000 Shares Sep 15 2010 
Dyax Corp. (DYAX) CFO George V Migausky buys 12,000 Shares Aug 25 2010 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Weekly CFO Buy Highlights: F.N.B. Corp, Great Wolf Resorts Inc, Dyax Corp, Transcat Inc, Cal Dive In Jun 20 2009 

More From Our Partners
Can the Rally in Dyax (DYAX) Shares Continue? - Tale of the Tape Apr 15 2015 - ZACKS

More From Other Websites
Nasdaq stocks posting largest volume increases Apr 20 2015
Nasdaq stocks posting largest percentage increases Apr 20 2015
Most active Nasdaq-traded stocks Apr 20 2015
Dyax Corp. to Host First Quarter 2015 Earnings Call and Webcast Apr 16 2015
Dyax Corp. to Host First Quarter 2015 Earnings Call and Webcast Apr 16 2015
Can the Rally in Dyax (DYAX) Shares Continue? - Tale of the Tape Apr 15 2015
Dyax Closes $230 Million Public Offering of Common Stock Apr 13 2015
Dyax Closes $230 Million Public Offering of Common Stock Apr 13 2015
Dyax Corp. to Participate in the 14th Annual Needham Healthcare Conference Apr 09 2015
Dyax Corp. to Participate in the 14th Annual Needham Healthcare Conference Apr 09 2015
DYAX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Apr 09 2015
Burlington biotech Dyax is now worth more than the maker of Sam Adams Apr 08 2015
Dyax Announces Pricing of $200 Million Public Offering of Common Stock Apr 08 2015
Dyax Announces Pricing of $200 Million Public Offering of Common Stock Apr 07 2015
Dyax Shares Defy Gravity on Secondary Offering News Apr 07 2015
Clovis Cancer 'Breakthrough,' Oculus Flop Top Biotech News Late Apr 06 2015
Viacom shares slip after hours on reorganzation Apr 06 2015
DYAX CORP Files SEC form 8-K, Results of Operations and Financial Condition Apr 06 2015
Dyax Announces Proposed Public Offering of 7,000,000 Shares of Common Stock Apr 06 2015
Dyax Announces Proposed Public Offering of 7,000,000 Shares of Common Stock Apr 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK